Antibiotic-resistant Mycobacterium tuberculosis strains are threatening progress in
containing the global tuberculosis epidemic. Mycobacterium tuberculosis is intrinsically …

Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

Background: The American Thoracic Society, US Centers for Disease Control and
Prevention, European Respiratory Society, and Infectious Diseases Society of America …

Inadequate dosing and incomplete treatment regimens, coupled with the ability of the
tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have …

For the successful treatment of pulmonary tuberculosis, drugs need to penetrate complex
lung lesions and permeate the mycobacterial cell wall in order to reach their intracellular …

Tuberculosis is the leading infectious cause of death worldwide, with 9· 6 million cases and
1· 5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR)
tuberculosis (TB) substantially challenges TB control, especially in the European Region of …

Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease.
With growing drug resistance the epidemic remains and will require significant attention and …

Tuberculosis is an airborne infectious disease treated with combination therapeutic
regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining …

Extensively drug-resistant tuberculosis is a burgeoning global health crisis mainly affecting
economically active young adults, and has high mortality irrespective of HIV status. In some …